30,343 Shares in Enovis Corporation $ENOV Bought by Illinois Municipal Retirement Fund

Illinois Municipal Retirement Fund acquired a new stake in Enovis Corporation (NYSE:ENOV) during the 3rd quarter, Holdings Channel reports. The institutional investor acquired 30,343 shares of the company’s stock, valued at approximately $921,000.

A number of other large investors also recently bought and sold shares of the company. Hood River Capital Management LLC lifted its stake in shares of Enovis by 20.3% in the 2nd quarter. Hood River Capital Management LLC now owns 1,735,533 shares of the company’s stock worth $54,426,000 after acquiring an additional 292,950 shares during the period. River Road Asset Management LLC raised its holdings in Enovis by 3.5% during the second quarter. River Road Asset Management LLC now owns 1,439,923 shares of the company’s stock worth $45,156,000 after purchasing an additional 48,036 shares in the last quarter. Boston Partners lifted its position in Enovis by 42.4% in the second quarter. Boston Partners now owns 1,382,724 shares of the company’s stock valued at $43,352,000 after purchasing an additional 411,744 shares during the period. Geode Capital Management LLC lifted its position in Enovis by 43.8% in the second quarter. Geode Capital Management LLC now owns 1,342,481 shares of the company’s stock valued at $42,105,000 after purchasing an additional 408,608 shares during the period. Finally, Tributary Capital Management LLC boosted its holdings in Enovis by 91.5% in the 3rd quarter. Tributary Capital Management LLC now owns 1,154,482 shares of the company’s stock valued at $35,027,000 after purchasing an additional 551,613 shares in the last quarter. Hedge funds and other institutional investors own 98.45% of the company’s stock.

Wall Street Analysts Forecast Growth

ENOV has been the subject of a number of analyst reports. UBS Group reissued a “buy” rating and set a $50.00 target price on shares of Enovis in a research note on Monday, January 5th. BTIG Research began coverage on Enovis in a report on Tuesday, January 6th. They set a “buy” rating and a $41.00 price objective on the stock. Evercore reissued an “outperform” rating on shares of Enovis in a report on Monday, January 12th. Canaccord Genuity Group decreased their target price on shares of Enovis from $58.00 to $50.00 and set a “buy” rating on the stock in a research report on Wednesday, December 17th. Finally, Wells Fargo & Company increased their price target on shares of Enovis from $41.00 to $42.00 and gave the company an “overweight” rating in a report on Friday, November 7th. Seven investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $46.71.

Enovis Stock Up 2.1%

ENOV opened at $22.08 on Thursday. The business’s fifty day moving average is $24.77 and its two-hundred day moving average is $28.39. The company has a debt-to-equity ratio of 0.66, a quick ratio of 1.16 and a current ratio of 2.22. The company has a market cap of $1.26 billion, a price-to-earnings ratio of -0.93 and a beta of 1.52. Enovis Corporation has a one year low of $21.00 and a one year high of $44.76.

Insider Activity

In other Enovis news, EVP Daniel A. Pryor sold 999 shares of the firm’s stock in a transaction dated Tuesday, December 9th. The shares were sold at an average price of $27.20, for a total transaction of $27,172.80. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider John Kleckner bought 2,468 shares of the business’s stock in a transaction on Tuesday, November 25th. The shares were acquired at an average price of $30.32 per share, with a total value of $74,829.76. Following the transaction, the insider owned 12,302 shares of the company’s stock, valued at $372,996.64. The trade was a 25.10% increase in their position. The disclosure for this purchase is available in the SEC filing. 2.70% of the stock is owned by insiders.

Enovis Company Profile

Enovis is a global medical technology company focused on advancing the field of musculoskeletal health. Formed through the separation of the MedTech business from Colfax Corporation in 2021, Enovis brings together a portfolio of specialized products and services designed to address conditions affecting the foot and ankle, hand and wrist, sports medicine, joint repair, biologics and rehabilitation.

The company’s flagship offerings include minimally invasive implants and instrumentation for foot and ankle surgery under the Treace Medical Concepts brand, focal joint resurfacing implants through Arthrosurface, and synthetic bone graft substitutes marketed as NovaBone.